

Oncology Evidence Network (OEN) - Publication list

Non-exhaustive –

Find out more on www.iqvia.com/solutions/real-world-evidence/evidence-networks/oncology-evidence-network

Overall capability

Vennin, S., Sopwith, W., Calvo, E., Cantoni, C., Del Valle, P.C., Maissenhaelter, B., Rippin, G., Ryll, B. and Osterwalder, B., 2025. **Sieving for gold: external comparator studies to prioritize drugs for late-stage clinical trial.** *Journal of Comparative Effectiveness Research*, (0), p.e240201.

Girardat-Rotar, L., Rudolph, A., Maissenhaelter, B., Cardenes, P. and MacDougall, F., 2025. **Archival Sample Testing for Real-World Insights: Innovative Approaches to Enriching Retrospective Studies With Biomarker Data.** *Value in Health*, 28(12), p.S607.

Borges, M., Russell, O., Cardenes, P., Girardat-Rotar, L., Maissenhaelter, B. and MacDougall, F., 2025. **Expediting Oncology Evidence Generation by Leveraging EMR-Enabled Clinically Rich Real-World Data at Scale.** *Value in Health*, 28(12), p.S620.

Earla, J.R., Ajmal, A., Bocquet, F., Del Valle, P.C., Dushkin, K., Prabhu, V.S., Ramakrishnan, K., Russell, O., Wang, L., Zheng, D. and Desai, K., 2024. **RWD19 Assessing the Ability of Hospital Sites From a European Real-World Network to Support Oncology Evidence Generation.** *Value in Health*, 27(12), p.S575.

Saunders, A., Hogg, C., Jeswani, N., Masi, D. and Papsch, R., 2022. **Examining the Fitness-for-Purpose of European Real-World Data Sources for External Comparators in Haematological Malignancies.** *Value in Health*, 25(12), p.S466.

Breast cancer

Campone, M., Frenel, J.S., Kiver, V.I., Woeckel, A., Kerscher, A., Krebs, M., Leal, C., Saglimbene, V.M., Ann, Q., Sadetsky, N. and Sjekloca, N., 2026. **Treatment patterns and clinical outcomes in chemotherapy-treated patients with HR+/HER2- metastatic breast cancer using real-world data in France and Germany.** *BMC cancer*.

Cottu, P., Sawyer, E., Frenel, J., Earla, J.R., Hirshfield, K.M., Gooud, G., Ntais, D., Jamotte, A., Perkins, C., Babonneau, A., Kitetere, E., Vallet, M., Riaz, M., Timbres, J., Haroun, L., Cirneanu, L., Hermans, R., Saglimbene, V., Dushkin, K., Ajmal, A., Oikonomou, S., Vladimirova, A., Desai, K., Bocquet, F., Hall, P.S., 2025. **Real-world clinical characteristics and treatment patterns among UK and French patients with a recent diagnosis (2020 onwards) of early-stage, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (ER+/HER2-eBC), SABCS**

Hall, P.S., Sawyer, E., Frenel, Desai, K., Hirshfield, K.M., Gooud, G., Ntais, D., Jamotte, A., Perkins, C., Babonneau, A., Kitetere, E., Vallet, M., Riaz, M., Timbres, J., Haroun, L., Cirneanu, L., Hermans, R., Saglimbene, V., Dushkin, K., Ajmal, A., Oikonomou, S., Vladimirova, Earla, J.R., Bocquet, F., Cottu, P., 2025. **Real-world clinical characteristics, treatment patterns and outcomes among UK and French patients with early-stage, estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer treated with neoadjuvant chemotherapy, SABCS**

Bocquet, F., Campone, M., Cottu, P.H., Callens, C., Patrão, A.S., Lopes-Conceição, L., Bianchi, M.A., Bayona, R.S., Fasching, P.A., Uhrig, S. and Huebner, H., 2025. **632eP Prevalence of ESR1 mutations in ER+/HER2-advanced breast cancer (aBC) patients treated with everolimus after CDK4/6 inhibitors.** *Annals of Oncology*, 36, p.S471.

Campone, M., Frenel, J.S., Kiver, V.I.I., Woeckel, A., Kerscher, A.G., Krebs, M., Leal, C.S., Saglimbene, V.M., Trankov, N., Sadetsky, N. and Sjekloca, N., 2024. **374P Real-world (Rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherapy (CT) in France and Germany.** *Annals of Oncology*, 35, pp.S375-S376.

Campone, M., Frenel, J.S., Kiver, V.I.I., Woeckel, A., Kerscher, A.G., Krebs, M., Leal, C.S., Saglimbene, V.M., Rehnquist, M.K., Sadetsky, N. and Sjekloca, N., 2024. **258P Real-world (rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2-negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherapy (CT) in France.** *ESMO Open*, 9.

Cottu, P., Cheeseman, S., Hall, P., Wöckel, A., Scholz, C.W., Bria, E., Orlandi, A., Ribelles, N., Vallet, M., Niklas, N. and Hogg, C., 2025. **Attrition between lines of therapy and real-world outcomes of patients with HER2-positive metastatic breast cancer in Europe: a cohort study leveraging electronic medical records.** *Breast cancer research and treatment*, 209(2), pp.419-430.

Hall, P., Cheeseman, S., Cottu, P., Krebs, M., Scholz, C., Vallet, M., Niklas, N., Hogg, C., Lucerna, M., Collin, S.M. and Logue, A., 2024. **Abstract PO3-16-11: Attrition rates from first-to third-line therapy in HER2+ metastatic breast cancer in Europe.** *Cancer Research*, 84(9_Supplement), pp.PO3-16.

Twelves, C., Cheeseman, S., Sopwith, W., Thompson, M., Riaz, M., Ahat-Donker, N., Myland, M., Lee, A., Przybysz, R., Turner, S. and Hall, G., 2020. **Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre.** *BMC cancer*, 20, pp.1-12.

Twelves, C., Cheeseman, S., Thompson, M., Riaz, M., Perren, T., Ahat-Donker, N., Sopwith, W., Myland, M., Lee, A., Turner, S. and Hall, G., 2019. **Abstract P4-13-14: “Real world” characteristics, treatment patterns and outcomes of patients with hormone receptor positive (HR+), human epidermal growth factor 2 negative (HER2-) metastatic breast cancer (MBC).** *Cancer Research*, 79(4_Supplement), pp.P4-13.

Endocrine tumours

Walter, T., Steinhagen, P.R., del Olmo, M., du Bourg, L.D.M., Bocquet, F., Kiesewetter-Wiederkehr, B., Gerard, L., Bolduan, F., Truong-Thanh, X.M., Pommie, C. and Houchard, A., 2025. **Secondary results from KINETICS, a real-world study of lanreotide autogel (LAN) in advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs) according to Ki67 proliferation index (Ki67).** *Annals of Oncology*, 36, p.S1014.

Vandamme, T., Steinhagen, P.R., del Olmo, M., du Bourg, L.D.M., Bocquet, F., Kiesewetter-Wiederkehr, B., Walter, T., Bolduan, F., Truong-Thanh, X.M., Pommie, C. and Houchard, A., 2025. **KINETICS: Real-world study of lanreotide autogel (LAN) in advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs) according to Ki67 proliferation index (Ki67).** *Annals of Oncology*, 36, p.S85.

Gastric cancer

Jones, S., Turner, L., Rashid, A., Gallinaro, J., Borges, M., Vitanova, K., Eldridge, E., Conill, M., Saglimbene, V. and Guerra, I., 2025. Jones, S., Turner, L., Rashid, A., Gallinaro, J., Borges, M., Vitanova, K., Eldridge, E., Conill, M., Saglimbene, V. and Guerra, I., 2025. **Landscape of Natural Language Processing (NLP) Capabilities at Clinical Sites: Insights From a Real-World (RW) Gastric Cancer (GC) Study.** *Value in Health*, 28(12), p.S627.

Head and Neck cancer

Mach, N., Renaux, J., Grogg, J., Osterwalder, B., Niklas, N., Maissenhaelter, B., Ajmal, A., Wolf, A.Y., Shaid, S., Borges, M., Conceição, L., Bento, M.J., Vieira, C.M., Rordorf, T., Brezina, T., Joerger, M. and Fernandez, E., 2022. **A008: Real-world comparator study: MVX-ONCO-1, a cell-based immunotherapy currently in Phase II, shows prolonged OS and PFS for patients with recurrent/metastatic Head & Neck squamous cell carcinoma (R/M HNSCC).** Presented at CICON 2022, New York.

Lung cancer

Christopoulos, P., Assmann, C., Zhang, L., Dunton, K., Ali, A., Berktaş, M., Delmastro, L., Strübing, A., Xiong, Y., Lay-Flurrie, S. and Hindocha, P., 2025. **Real-World Characteristics, Treatment Patterns, and Outcomes in Advanced HER2 (ERBB2)-Mutant Non-Small Cell Lung Cancer: A Retrospective Study of Single Centers in France and Germany.** *Clinical Therapeutics*.

Chouaid, C., Lee, A., De Cabo, H.B., Christopoulos, P., Correia, B., Deshayes, S., Gonzalez, A.E., Girard, N., Lopes-Conceição, L., Mella, M. and Moreira, J., 2025. **Real-world treatment patterns and survival in patients (pts) with ROS1-positive (ROS1+) locally advanced or metastatic (LAM) non-small cell lung cancer (NSCLC) in Canada and Europe.** *Annals of Oncology*, 36, pp.S1131-S1132.

Wolf, A., Stratmann, J.A., Shaid, S., Niklas, N., Calleja, A., Ubhi, H., Munro, R., Waldenberger, D., Carroll, R., Daumont, M.J. and Penrod, J.R., 2023. **Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012–2018.** *BMC Pulmonary Medicine*, 23(1), p.16.

Provencio, M., Carcereny, E., Castro, R.L., Calvo, V., Abreu, D.R., Cobo, M., Ortega, A.L., Bernabé, R., Guirado, M., Massutí, B. and del Barco-Morillo, E., 2023. **Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study.** *Translational Lung Cancer Research*, 12(10), p.2113.

Christopoulos, P., Girard, N., Zhang, L., Mbanya, Z., Dunton, K., Ali, A., Berktaş, M., Delmastro, L., Struebing, A., Xiong, Y. and Lay-Flurrie, S., 2023. **1390P Real-world characteristics, treatment patterns and outcomes of patients with advanced HER2/ERBB2-mutant non-small cell lung cancer (NSCLC) in France and Germany.** *Annals of Oncology*, 34, pp.S796-S797.

Baltus, H., Waldmann, A., Leal, C., Saglimbene, V., Schoemaker, M.J., Evans-Cheung, T., Rault, C., Daumont, M., Emanuel, G., Lucherini, S. and Vo, L., 2023. **EPH82 Real-World Outcomes in Patients with Resected Non-Small Cell Lung Cancer (NSCLC) Receiving (NEO) Adjuvant Treatment in Germany: An IO Optimise Analysis.** *Value in Health*, 26(12), pp.S217-S218.

Daumont, M.J., Rault, C., Baltus, H., Ding, P.Q., Emanuel, G., Lucherini, S., Vo, L., Greystoke, A., Katalinic, A., Leal, C. and Muwaffak, M., 2023. **P1. 25-05 Real-World Outcomes in Non-metastatic**

Non-small Cell Lung Cancer (NSCLC): An IO Optimise Multi-Country Analysis. *Journal of Thoracic Oncology*, 18(11), pp.S269-S270.

Waldmann, A., Leal, C., Schoemaker, M.J., Niklas, N., Labohm, L., Baltus, H., Rault, C., Daumont, M.J., Emanuel, G., Muwaffak, M. and Saglimbene, V., 2023. **EP08. 02-04 Real-World Disease-Free Survival (DFS) in Non-metastatic Non-small Cell Lung Cancer (NSCLC): A German IO Optimise Analysis.** *Journal of Thoracic Oncology*, 18(11), pp.S569-S570.

Girard, N., Popat, S., Rahhali, N., Rodrigues, B., Schioppa, C.A., Pick-Lauer, C., Adamczyk, A., Sermon, J., Diels, J., Penton, J. and Thomas, M., 2022. **1117P Amivantamab compared with European, real-world (RW) standard of care (SoC) in adults with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), after failure of platinum-based therapy.** *Annals of Oncology*, 33, p.S1062.

Soares, M., Antunes, L., Redondo, P., Borges, M., Hermans, R., Patel, D., Grimson, F., Munro, R., Chaib, C., Lacoïn, L. and Daumont, M., 2021. **Treatment and outcomes for early non-small-cell lung cancer: A retrospective analysis of a Portuguese hospital database.** *Lung Cancer Management*, 10(2), p.LMT46.

Soares, M., Antunes, L., Redondo, P., Borges, M., Grimson, F., Hermans, R., Chaib, C., Lacoïn, L., Juarez-Garcia, A., Daumont, M.J. and Penrod, J.R., 2021. **Small cell lung cancer treatment and survival in Portugal: A retrospective analysis from the I-O Optimise initiative.** *European Journal of Cancer Care*, 30(6), p.e13496.

Snee, M., Cheeseman, S., Thompson, M., Riaz, M., Sopwith, W., Lacoïn, L., Chaib, C., Daumont, M.J., Penrod, J.R., O'Donnell, J.C. and Hall, G., 2021. **Trends in the prescription of systemic anticancer therapy and mortality among patients with advanced non-small cell lung cancer: a real-world retrospective observational cohort study from the IO optimise initiative.** *BMJ open*, 11(5), p.e043442.

Snee, M., Cheeseman, S., Thompson, M., Riaz, M., Sopwith, W., Lacoïn, L., Chaib, C., Daumont, M.J., Penrod, J.R. and Hall, G., 2021. **Treatment patterns and survival outcomes for patients with non-small cell lung cancer in the UK in the preimmunology era: a REAL-Oncology database analysis from the IO Optimise initiative.** *BMJ open*, 11(9), p.e046396.

Soares, M., Antunes, L., Oliveira-Gomes, J., Paupério, G., Cardia, J., Redondo, P., Borges, M., Chaib, C., Lacoïn, L., Grimson, F. and Ralphs, E., 2021. **P09. 42 Second-Line Immunotherapy Treatment Patterns in Non-Small Cell Lung Cancer in Portugal: An IO Optimise Cohort Study.** *Journal of Thoracic Oncology*, 16(3), pp.S309-S310.

Soares, M., Antunes, L., Redondo, P., Borges, M., Hermans, R., Patel, D., Grimson, F., Munro, R., Chaib, C., Lacoïn, L. and Daumont, M., 2020. **Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the IO Optimise initiative.** *BMC Pulmonary Medicine*, 20, pp.1-13.

Ekman, S., Griesinger, F., Baas, P., Chao, D., Chouaid, C., O'Donnell, J.C., Penrod, J.R., Daumont, M., Lacoïn, L., McKenney, A. and Khovratovich, M., 2019. **IO Optimise: a novel multinational real-world research platform in thoracic malignancies**. *Future Oncology*, 15(14), pp.1551-1563.

Soares, M.A.S., Antunes, L., Redondo, P., Borges, M., Hermans, R., Patel, D., Grimson, F., Munro, R., Chaib, C., Lacoïn, L. and Daumont, M., 2019. **Treatment (Tx) patterns and overall survival (OS) in patients (pts) with stage IIIB–IV NSCLC in Portugal: An IPO-PORTO database analysis from the IO Optimise initiative**. *Annals of Oncology*, 30, pp.ii15-ii16.

Soares, M., Antunes, L., Redondo, P., Borges, M., Grimson, F., Hermans, R., Chaib, C., Lacoïn, L., Juarez-Garcia, A., Daumont, M.J. and Penrod, J.R., 2021. **Small cell lung cancer treatment and survival in Portugal: A retrospective analysis from the I-O Optimise initiative**. *European Journal of Cancer Care*, 30(6), p.e13496.

Snee, M., Cheeseman, S., Thompson, M., Bowman, R., Lacoïn, L., Sopwith, W., Chaib, C., Juarez-Garcia, A., Daumont, M., Penrod, J.R. and O'Donnell, J.C., **Small Cell Lung Cancer Treatment and Survival in the UK: a REAL-Oncology Analysis From the IO Optimise Initiative**.

Snee, M., Cheeseman, S., Thompson, M., Bowman, R., Lacoïn, L., Sopwith, W., Chaib, C., Daumont, M., Penrod, J.R., O'Donnell, J.C. and Hall, G., 2019. **Impact of second-line (2L) immune checkpoint inhibitors (ICIs) on the treatment (Tx) of advanced non-small cell lung cancer (NSCLC) in a UK centre: A REAL-oncology analysis from the IO Optimise initiative**. *Annals of Oncology*, 30, p.v616.

Snee, M., Cheeseman, S., Thompson, M., Riaz, M., Lacoïn, L., Sopwith, W., Chaib, C., Daumont, M., Penrod, J.R., O'Donnell, J.C. and Hall, G., 2019. **Temporal trends in treatment (Tx) and overall survival (OS) among patients (pts) with incident NSCLC in the UK: a real-oncology database analysis from the IO Optimise initiative**. *Annals of Oncology*, 30, pp.ii14-ii15.

Sørensen, J.B., Ekman, S., Brustugun, O.T., Horvat, P., Patel, D., Rosenlund, M., Kejs, A.M., Juarez-Garcia, A., Daumont, M., Lacoïn, L. and Penrod, J.R., 2019. **Evolution of overall survival (OS) in patients (pts) with incident NSCLC in Denmark and Sweden: a SCAN-LEAF study analysis from the IO Optimise initiative**. *Annals of Oncology*, 30, pp.ii16-ii17.

Ekman, S., Horvat, P., Rosenlund, M., Kejs, A.M., Patel, D., Juarez-Garcia, A., Lacoïn, L., Daumont, M.J., Penrod, J.R., Brustugun, O.T. and Sørensen, J.B., 2021. **Epidemiology and survival outcomes for patients with NSCLC in Scandinavia in the Preimmunotherapy era: a SCAN-LEAF retrospective analysis from the IO optimise initiative**. *JTO Clinical and Research Reports*, 2(5), p.100165.

Horvat, P., Mette-Kejs, A., Ann, Q., Lascano, V., Bray, B., Patel, D., Ekman, S., Lacoïn, L., Juarez-Garcia, A. and Kim, J., 2019, August. **Swedish National Registries versus electronic medical records: Comparing the completeness of systemic therapy data using data from the SCAN-LEAF study**. In *PHARMACOEPIDEMIOLOGY AND DRUG SAFETY* (Vol. 28, pp. 208-208). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY.

Snee, M., Cheeseman, S., Thompson, M., Lacoïn, L., Sopwith, W., Godden, P., Chaib, C., Daumont, M., Penrod, J.R., O'Donnell, J. and Hall, G., 2018. **P82 Treatment patterns in patients with stage IIIB-IV NSCLC in clinical practice: retrospective analysis of a UK trust database.**

Snee, M., Cheeseman, S., Thompson, M., Godden, P., Sopwith, W., Chaib, C., Juarez-Garcia, A., Lacoïn, L., Penrod, J.R. and Hall, G., **Clinical Characteristics and Overall Survival of Patients Diagnosed With Non-Small Cell Lung Cancer (2006-2017) in Routine Clinical Practice: A Retrospective Analysis of a UK Hospital Database.**

Sørensen, J.B., Ekman, S., Horvat, P., Layton, D., Kim, J., Rosenlund, M., Juarez-Garcia, A., Daumont, M., Jacobs, H.C., Lacoïn, L. and Brustugun, O.T., 2018. **Initial treatment in patients (pts) diagnosed with non-small cell lung cancer (NSCLC) in Denmark from 2005-2015: The SCAN-LEAF study.** *Annals of Oncology*, 29, pp.viii536-viii537.

Ekman, S., Planck, M., Sørensen, J.B., Horvat, P., Layton, D., Kim, J., Rosenlund, M., Juarez-Garcia, A., Daumont, M., Jacobs, H.C. and Lacoïn, L., 2018. **Treatment patterns in patients (pts) with stage IIIB-IV non-small cell lung cancer (NSCLC) in Sweden: The SCAN-LEAF study.** *Annals of Oncology*, 29, p.viii537.

Ekman, S., Planck, M., Brustugun, O.T., Horvat, P., Layton, D., Kim, J., Rosenlund, M., Juarez-Garcia, A., Daumont, M., Jacobs, H.C. and Lacoïn, L., **Healthcare Resource Utilisation Among Patients With Non-Small Cell Lung Cancer (NSCLC) in Sweden: The SCAN-LEAF Study.** *Lung*, 15(224), pp.92-9.

Ekman, S., Planck, M., Brustugun, O.T., Rockberg, J., Juarez-Garcia, A., Daumont, M.M., Huang, H., Pereira, M., Svård, J., Rosenlund, M. and Chirita, O., 2017. MA 18.14 **Non-Small Cell Lung Cancer (NSCLC) Treatment and Survival in Scandinavia: The SCAN-LEAF Study.** *Journal of Thoracic Oncology*, 12(11), pp.S1881-S1882.

Sandelin, M., Planck, M., Sorensen, J.B., Brustugun, O.T., Rockberg, J., Juarez-Garcia, A., Layton, D., Daumont, M.M., Huang, H., Pereira, M. and Svard, J., 2017, November. **Non-Small Cell Lung Cancer (NSCLC) Patient Characteristics and Clinical Care Insights in Sweden: The SCAN-LEAF Study.** In *JOURNAL OF THORACIC ONCOLOGY* (Vol. 12, No. 11, pp. S1989-S1989). STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA: ELSEVIER SCIENCE INC.

Durand-Zaleski, I., Manley-Daumont, M., Baas, P., Chaib, C., Chao, D., Chouaid, C., Ekman, S., d'Estrube, T., Griesinger, F., Juarez-Garcia, A. and Khovratovich, M., 2017. **IO Optimise: developing a unique multinational real-world evidence-based research platform in oncology.** *Value in Health*, 20(9), pp.A742-A743.

Ekman, S., Sørensen, J.B., Rockberg, J., Sandelin, M., Daumont, M., Sobocki, P., Klint, P., Huang, H.Y., Svård, J., Chirita, O. and Jørgensen, L., 2017. **P1. 06-041 Overall Survival and Intermediate Outcomes among Scandinavian Non-Small Cell Lung Cancer Patients: The SCAN-LEAF Study: Topic: Advanced General.** *Journal of Thoracic Oncology*, 12(1), p.S691.

Snee, M., Cheeseman, S., Levick, B., Hall, G., Rohde, G., Stratmann, J., Wolf, A., van Gils, C., Griner, R., Mahmood, A. and Niklas, N., 2022. **44P Real-world (RW) treatment patterns, patient characteristics and outcomes in advanced non-small cell lung cancer (aNSCLC) with PD1/L1 as first-line (1L) therapy in the UK and Germany.** *Annals of Oncology*, 33, pp.S52-S53.

Lymphoma

Bachy, E., Harnett, J., Luminari, S., Prochazka, K., Townsend, W., Radford, J., Serna, Á., Kim, T.M., Kuruvilla, J., Damaj, G.L. and Jiménez-Ubieto, A., 2025. **Comparative effectiveness of onronextamab versus real-world systemic therapies used in an external control arm in patients with relapsed/refractory follicular lymphoma.** *Hematological Oncology*, 43, p.e583_70096.

Luminari, S., Harnett, J., Thieblemont, C., Prochazka, K., Townsend, W., Radford, J., Serna, Á., Jalbert, J.J., Kamat, S., Wang, J. and Ambati, S.R., 2024. **Results from the follicular lymphoma (FL) outcomes in patients (pts) with relapsed/refractory (R/R) disease treated with systemic therapy in a real-world assessment (FLORA) study.**

Bachy, E., Damaj, G.L., Ma, Q., Hampp, C., Harnett, J., Sobel, R.E., Jalbert, J.J., Quek, R.G., Wei, W., Wu, N. and Mastey, V., 2022. **Trial in Progress: Follicular Lymphoma Outcomes in Relapsed/Refractory Patients Treated with Systemic Therapy in a Real-World Assessment (FLORA).** *Blood*, 140(Supplement 1), pp.5198-5200.

Damaj, G.L., Hampp, C., Bachy, E., Prochazka, K., Jo, J.C., Kim, T.M., Oberic, L., Townsend, W., Jalbert, J.J., Ma, Q. and Kamat, S., 2024. **Outcomes in patients (pts) with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) treated with systemic therapy from real world experience (ORCHID) study.**

Thieblemont, C., Qiufei, M.A., Hampp, C., Harnett, J., Sobel, R.E., Jalbert, J.J., Quek, R.G., Wei, W., Wu, N., Mastey, V. and Wang, J., 2023. **PB2357: TRIAL IN PROGRESS: OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH SYSTEMIC THERAPY FROM REAL-WORLD EXPERIENCE (ORCHID).** *HemaSphere*, 7(S3), p.e6096515.

Palomba, M.L., Ghione, P., Patel, A.R., Nahas, M., Beygi, S., Hatswell, A.J., Kanters, S., Limbrick-Oldfield, E.H., Wade, S.W., Ray, M.D. and Owen, J., 2023. **A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.** *Expert review of anticancer therapy*, 23(2), pp.199-206.

Palomba, M.L., Ghione, P., Patel, A.R., Deighton, K., Jacobson, C., Nahas, M., Jung, A.S., Hatswell, A.J., Kanters, S., Limbrick-Oldfield, E. and Wade, S.W., 2021. **A comparison of clinical outcomes from updated Zuma-5 (axicabtagene ciloleucel) and the international SCHOLAR-5 external control cohort in relapsed/refractory follicular lymphoma (R/R FL).** *Blood*, 138, p.3543.

Ghione, P., Ghesquieres, H., Bobillo, S., Patel, A.R., Kanters, S., Deighton, K., Dong, H., Yang, Y., Ma, L., Limbrick-Oldfield, E.H. and Thornton Snider, J., 2021. **OUTCOMES IN LATER-LINES OF THERAPY FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: RESULTS FROM THE INTERNATIONAL SCHOLAR-5 STUDY.** *Hematological Oncology*, 39.

Ghione, P., Palomba, M.L., Patel, A.R., Bobillo, S., Deighton, K., Jacobson, C.A., Nahas, M., Hatswell, A.J., Jung, A.S., Kanters, S. and Snider, J.T., 2022. **Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.** *Blood, The Journal of the American Society of Hematology*, 140(8), pp.851-860.

Ghione, P., Palomba, M.L., Ghesquieres, H., Bobillo, S., Patel, A.R., Nahas, M., Kanters, S., Deighton, K., Hatswell, A., Ma, L. and Limbrick-Oldfield, E.H., 2022. **Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study.** *Haematologica*, 108(3), p.822.

Multiple Myeloma

Jagannath, S., Lin, Y., Goldschmidt, H., Reece, D., Nooka, A., Senin, A., Rodriguez-Otero, P., Powles, R., Matsue, K., Shah, N. and Anderson Jr, L.D., 2021. **KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma.** *Blood cancer journal*, 11(6), p.116.

Couto, M.E., Borges, M., Bento, M.J., Calisto, R., Magalhaes, M.D.M., Ajmal, A., Niklas, N., Dushkin, K., MacDougall, F., Wolf, A. and Shaid, S., 2021. **Treatment Patterns and Outcomes in Lenalidomide-Exposed Multiple Myeloma Patients in Real-World Settings: A Multi-Center Retrospective Study.** *Blood*, 138, p.5012.

Ovarian cancer

Fagotti, A., Frenel, J.S., Saint-Ghislain, M., Lim, J., Boyle, T.A.C., Golembesky, A., Lee, H., Vitanova, K., Nam, Y. and Braicu, I., 2025. **Real-world (rw) outcomes in patients (pts) with advanced ovarian cancer (aOC) receiving niraparib (nir) as first-line maintenance (1LM) in the EUROPA study.** *Annals of Oncology*, 36, pp.S736-S737.

Fagotti, A., Braicu, E., Frenel, J.S., Saint-Ghislain, M., Wirtz, M., Lim, J., Boyle, T., Mascialino, B., Arnold, K., Chaparova, E. and Hogg, C., 2024. **The real-world use of first-line maintenance treatment regimens among patients with advanced ovarian cancer varies by biomarker status: results from the Europa study.** *International Journal of Gynecological Cancer*, 34, pp.A211-A212.

Cheeseman, S., Levick, B., Sopwith, W., Fenton, H., Nam, E.J., Kim, D., Lim, S., Martin, E., Frenel, J.S., Bocquet, F. and Kubelac, P., 2023. **Ovarian Real-World International Consortium (ORWIC):**

A multicentre, real-world analysis of epithelial ovarian cancer treatment and outcomes. *Frontiers in Oncology*, 13, p.1114435.

Hall, G., Cheeseman, S., Levick, B., Nam, E.J., Lim, S., Classe, J.M., Martin, E., Kubelac, P., Achimaş-Cadariu, P., Savva-Bordalo, J. and Borges, M., 2021. **An international, multicenter, real-world analysis of epithelial ovarian cancer treatment and outcomes.**

Levick, B., Cheeseman, S., Nam, E.J., Doh, H., Lim, S., Kim, D., Bocquet, F., Martin, E., Kubelac, P., Achimaş-Cadariu, P. and Calisto, R., 2021. **OEN: Multi-center, international, real-world evidence studies performed using health records without data pooling—The use of a common data model and shared analytical methods.**

Cheeseman, S., Levick, B., Sopwith, W., Fenton, H., Nam, E.J., Kim, D., Lim, S., Martin, E., Frenel, J.S., Bocquet, F. and Kubelac, P., 2023. **Ovarian Real-World International Consortium (ORWIC): A multicentre, real-world analysis of epithelial ovarian cancer treatment and outcomes.** *Frontiers in Oncology*, 13, p.1114435.

Urothelial cancer

Cheeseman, S., Thompson, M., Sopwith, W., Godden, P., Seshagiri, D., Adedokun, L., Zucker, K., Jain, S., Kotwal, S., Prescott, S. and Henry, A., 2020. **Current treatment and outcomes benchmark for locally advanced or metastatic urothelial cancer from a large UK-based single centre.** *Frontiers in Oncology*, 10, p.167.